Literature DB >> 18713230

Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study.

A C Davaine1, A Saraux, S Prigent, I Kupfer-Bessaguet, D Roswag, P Plantin, P Schoenlaub, F Talarmin, A Zagnoli, L Misery.   

Abstract

BACKGROUND: Anti-tumour necrosis factors (anti-TNF) are more and more used, but the rate of skin adverse events is not known.
OBJECTIVE: The aim was to assess the number of skin infections and other dermatoses in patients treated with anti-TNFalpha. PATIENTS AND METHODS: One hundred eighty-seven patients suffering from rheumatoid arthritis or ankylosing spondylitis underwent a dermatological exam. Patients with anti-TNF were compared with those without this treatment in a prospective transversal study.
RESULTS: Among them, 59 patients were treated with anti-TNFalpha and steroids were prescribed in 100 cases. There was no difference in the prevalence of skin infections or eczema or tumours. Skin drug reactions were observed in six patients. Infections by dermatophytes appear very frequent, approaching 70% in both groups.
CONCLUSIONS: This study shows that skin infections (or other skin diseases) are not more frequent in these patients. No differences were observed in infections (bacterial fungal, parasital or viral), tumours, psoriasis or the manifestations of atopic dermatitis. Nonetheless, a long-term survey might be interesting, especially about skin tumours.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713230     DOI: 10.1111/j.1468-3083.2008.02935.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

Review 1.  Safety of biologic therapy in rheumatoid arthritis.

Authors:  Robert S Woodrick; Eric M Ruderman
Journal:  Nat Rev Rheumatol       Date:  2011-10-11       Impact factor: 20.543

Review 2.  Therapeutic perspectives in atopic dermatitis.

Authors:  Laurent Misery
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

3.  [Undesired cutaneous adverse drug reactions: What is new?].

Authors:  R Treudler; J C Simon
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

4.  Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.

Authors:  Irene Pontikaki; Edit Shahi; Lucretia Adina Frasin; Raffaele Gianotti; Carlo Gelmetti; Valeria Gerloni; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  Tumor Necrosis Factor Inhibitor-Induced Eczematous Eruption: A Report of Two Cases and Review of the Literature.

Authors:  Sohemi Pagan-Leon; Tyler Werbel; Marjorie Montanez-Wiscovich
Journal:  Cureus       Date:  2021-05-17

6.  Adalimumab in recalcitrant severe psoriasis associated with atopic dermatitis.

Authors:  Savas Yayli; Nathalie Irla; Nikhil Yawalkar
Journal:  Case Rep Dermatol       Date:  2013-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.